Prospective Multicentr Longitudinal Study to Evaluate the Safet and Clinical Radiological Outcomes in the First Two Years of the Ambrace Model Reverse Shoulder Arthroplasty.

The use of inverted prostheses to replace shoulder joints damaged by degenerative or traumatic processes has become widespread over the past three decades. Current designs, used correctly, can restore function and improve pain in the majority of patients in whom they are implanted.

However, there are complications associated with shoulder arthroplasty surgery, such as wear of the prosthetic components, infection, allergy to the prosthetic components, or failure to restore full shoulder function. The occurrence of these complications is affected by multiple factors dependent on the subject, the surgeon and/or the implant used.

The EMBRACE Reverse Shoulder Arthroplasty System (LINK Spain) is a new model of reverse shoulder prosthesis introduced to the European market in August 2020. It is authorised for use in the treatment of degenerative or traumatic processes of the shoulder in the European Community. It has been in regular use at our centre since October 2020, and more than 50 prostheses of this model have been implanted this year.

There is an ongoing study at the Hospital Universitario Ramón y Cajal, with code PROTESISHOMBRO01, which carries out a prospective registry of all shoulder prostheses implanted at the centre. The present study, PROTESISHOMBRO02, will be carried out in conjunction with this one and differs from the previous one in that: 1.-It carries out a somewhat more exhaustive analysis of a subgroup of the patients included in the PROTESISHOMBRO01 study, and 2. The aim is to carry out a more detailed follow-up of the subjects who are implanted with this prosthetic model on a primary basis, analysing the clinical and radiological results and evaluating the presence of adverse effects of the prosthesis or short-term complications. For this purpose, subjects will be closely monitored for two years.